Facial Flush Reaction after Alcohol Ingestion during Topical Pimecrolimus and Tacrolimus Treatment

Facial flush reaction after alcohol ingestion during topical pimecrolimus and tacrolimus treatment.

tion of small quantities of beer or wine. The patients reported the sudden onset of an itching-burning sensation quickly followed by flushing. The facial reaction occurred within 5 and 10 min after the alcohol ingestion and between 2 and 4 weeks after the start of the treatment. The erythema was confined not only to the treated facial areas, but it also extended to the healthy skin, and its tot...

Periorbital erythema following alcohol ingestion during treatment with topical tacrolimus.

A 32-year-old man, who was undergoing treatment for eyelid dermatitis with topical tacrolimus ointment 0.1% (0.5 g applied twice daily for 1 wk), presented with periorbital erythema accompanied by a mild burning sensation that developed 30 minutes after he ingested one alcoholic beverage (Figure 1). The eruption was limited to the application site and resolved within one to two hours. Tacrolimu...

[Alcohol intolerance with facial flushing due to topical pimecrolimus treatment].

[Topical pimecrolimus and tacrolimus and the risk of cancer].

In this review the controversy regarding the association between topical pimecrolimus and tacrolimus and the development of tumors is unfolded. After reviewing the literature we conclude that, currently, there is no scientific evidence of an increased incidence of skin cancer, lymphomas or systemic immunosuppression in those patients that use or have used topical calcineurin inhibitors. Publish...

Four cases of facial discoid lupus erythematosus successfully treated with topical pimecrolimus or tacrolimus.

Discoid lupus erythematosus (DLE), which is a cutaneous form of lupus erythematosus (LE), is generally refractory to a wide range of topical or systemic therapies. Although the main treatment option for DLE is topical steroids, it is often ineffective or likely to produce long-term side effects. New drugs, including tacrolimus and pimecrolimus, have been developed to overcome the adverse effect...